It slows gastric emptying, which helps control blood sugar and prolongs satiety
Benefits Seen in High-Risk Patients The strongest benefits were observed in individuals already considered at high cardiovascular risk, including people with obesity, type 2 diabetes, or existing heart disease
Additionally, secondary causes of steatosis, such as viral hepatitis or autoimmune hepatitis, must be ruled out (4, 5)
Potential Clinical Consequences of Unintended Intramuscular Injection Rapid absorption from IM tirzepatide may cause acute nausea, vomiting, and gastrointestinal distressespecially in patients with low GLP1R pathway sensitivity or those beginning therapy
The SURPASS-CVOT trial established cardiovascular non-inferiority for tirzepatide compared with dulaglutide, alongside improvements in cardiometabolic risk factors
The method outlined here describes a 3-step process used to assess the impact UAA can have on the HLA binding potential of a peptide and to ultimately select naturally occurring proxies for commonly encountered UAA